This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research Article
Minghao Fang
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Corresponding Author
ORCiD: https://orcid.org/0000-0001-5310-8128
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Purpose: The study is to describe the clinical characteristics, outcomes and follow-up of cancer patients with COVID-19.
Methods: Clinical records, demographic data, signs and symptoms, laboratory results, cytokine profiles, chest CT scans, comorbidities, treatments, clinical outcomes, and RT-PCR of SARS-CoV-2 after discharge were retrospectively collected for fifty-six cancer patients with laboratory-confirmed COVID-19 pneumonia who were admitted to Tongji Hospital of Huazhong University of Science and Technology, Wuhan, China, from Feb 1 to Apr 1, 2020. Evidence of cytokine profiles were assessed by testing for the IL1β, IL2R, IL6, IL8, IL10, and TNF - α in the peripheral blood of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) infected cancer patients.
Results: Of 2143 patients with COVID-19, 56 cancer patients were included. The patients were divided into two groups, as cancer survivors, and cancer non-survivors. 12 (21%) patients with lymphopenia (0.5 [0.3-0.7]) had died during hospital stay. In non-survivors, IL2R, IL6, and IL10 were higher. 3(6.8%) cancer survivors with COVID-19 had positive RT-PCR test results again shortly after discharge.
Conclusion: The mortality rate of COVID-19 among cancer patients are considerable. Cancer non-survivors are characterized by more severe lymphopenia and a higher levels of cytokines. Recovered cancer survivors still may be virus carriers.
Keywords
COVID-19, SARS-CoV-2, cancer, lymphopenia, cytokines, virus carriers
Figure 1
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 08 Jun, 2020
Community comments: 1
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This is a preprint. It has not completed peer review.
Research Article
Minghao Fang
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Corresponding Author
ORCiD: https://orcid.org/0000-0001-5310-8128
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 08 Jun, 2020
Community comments: 1
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Purpose: The study is to describe the clinical characteristics, outcomes and follow-up of cancer patients with COVID-19.
Methods: Clinical records, demographic data, signs and symptoms, laboratory results, cytokine profiles, chest CT scans, comorbidities, treatments, clinical outcomes, and RT-PCR of SARS-CoV-2 after discharge were retrospectively collected for fifty-six cancer patients with laboratory-confirmed COVID-19 pneumonia who were admitted to Tongji Hospital of Huazhong University of Science and Technology, Wuhan, China, from Feb 1 to Apr 1, 2020. Evidence of cytokine profiles were assessed by testing for the IL1β, IL2R, IL6, IL8, IL10, and TNF - α in the peripheral blood of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) infected cancer patients.
Results: Of 2143 patients with COVID-19, 56 cancer patients were included. The patients were divided into two groups, as cancer survivors, and cancer non-survivors. 12 (21%) patients with lymphopenia (0.5 [0.3-0.7]) had died during hospital stay. In non-survivors, IL2R, IL6, and IL10 were higher. 3(6.8%) cancer survivors with COVID-19 had positive RT-PCR test results again shortly after discharge.
Conclusion: The mortality rate of COVID-19 among cancer patients are considerable. Cancer non-survivors are characterized by more severe lymphopenia and a higher levels of cytokines. Recovered cancer survivors still may be virus carriers.
Figure 1
Loading...